KALV News and Press, KalVista Pharmaceuticals Inc. From 12/27/22

KalVista Pharmaceuticals ( NASDAQ: KALV ) is selling common shares and warrants to institutional investors in a registered direct offering to raise gross proceeds of ~$58M. The company is selling ~9.48M common shares at $6 per share and 182.47K prefunded warrants at $5.999 fo...

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it has entered into a subscription agreement with institutional investors to sel...

KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q2 GAAP EPS of -$0.90 beats by $0.16 . Cash, cash equivalents and marketable securities were $122.3 million as of October 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketa...

– Results show the impact of attacks on mental health, daily activities, and quality of life in people living with HAE - – Real-world data demonstrate treatment burden associated with on-demand parenteral HAE therapies - KalVista Pharmaceuticals, Inc. (...

KalVista Pharmaceuticals ( NASDAQ: KALV ) on Monday reported data from a phase 1 trial of an orally disintegrating tablet (ODT) formulation of its drug sebetralstat. Sebetralstat is currently being developed in a phase 3 trial called KONFIDENT as a therapy for hereditary...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulatio...

- The discovery and optimization of sebetralstat published in the Journal of Medicinal Chemistry - - Data on absorption, metabolism, and excretion of sebetralstat reported in the journal Xenobiotica - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical ...

KalVista Pharmaceuticals ( NASDAQ: KALV ) has appointed current Board member Brian J.G. Pereira, M.D, as Chairman, effective immediately succeeding Martin Edwards, MD, who has resigned from the Board in a planned transition. For further detai...

– Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibit...

Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the s...